3 completed, 2 recruiting, 1 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Lung Adenocarcinoma Metastatic: new trials by email Literature Review of Lung Adenocarcinoma Metastatic trials Research Report on Lung Adenocarcinoma Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) - Lung Adenocarcinoma Metastatic | Phase 2 | Recruiting | Taipei Medical University Hospital | 50 | 2026-06-09 | 2026-06-18 |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 70 | 2025-03-31 | 2026-06-12 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) Durvalumab, Vinorelbine, Gemcitabine - Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 200 | 2017-12-14 | 2023-06-15 |
| Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC Radiotherapy, Nivolumab - Carcinoma，Non-Small-Cell Lung, Metastatic Lung Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 101 | 2017-02-10 | 2021-01-13 |
| A+C in Metastatic Lung Adenocarcinoma Cancer Crizotinib, bevacizumab - Lung Adenocarcinoma Metastatic | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2016-07-01 | 2016-11-02 |
| EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA LC-RT-PCR and NGS - Lung Adenocarcinoma Metastatic | Completed | University Hospital, Essen | 48 | 2015-03-01 | 2016-11-29 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Neoplasms by Site (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Lung Diseases (3) · Neoplasms (3) · Respiratory Tract Diseases (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adenoma (1) · Adnexal Diseases (1)
Carboplatin (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Crizotinib (1) · Gemcitabine (1) · Nivolumab (1) · Pemetrexed (1) · Radiotherapy (1) · Vinorelbine (1) · durvalumab (1)
AIO-Studien-gGmbH (2) · Chinese PLA General Hospital (1) · Context Therapeutics Inc. (1) · Taipei Medical University Hospital (1) · University Hospital, Essen (1)
Germany (2) · China (1) · Taiwan (1) · United States (1)
Chao-Hua Chiu (1) · Farastuk Bozorgmehr, Dr. (1) · Jonas Kuon, Dr (1) · Karen Chagin, MD (1)
PMID 31703637, PMID 32321565, PMID 40702361
2015 (1), 2016 (1)